A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma.

Trial Profile

A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Rindopepimut (Primary) ; Bevacizumab; Granulocyte macrophage colony stimulating factor; Keyhole limpet haemocyanin
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms ReACT
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 25 Feb 2016 Status changed from active, no longer recruiting to completed, according to Celldex Therapeutics Inc media release.
    • 20 Nov 2015 Results presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), as per Celldex Therapeutics media release.
    • 20 Nov 2015 Results published in Celldex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top